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Background: CO2 retention and skeletal muscle atrophy occur in patients with lung diseases and are associated with poor
clinical outcomes.
Results: Hypercapnia leads to AMPK/FoxO3a/MuRF1-dependent muscle fiber size reduction.
Conclusion: Hypercapnia activates a signaling pathway leading to skeletal muscle atrophy.
Significance: High CO2 levels directly activate a proteolytic program of skeletal muscle atrophy which is of relevance to patients
with lung diseases.
Patients with chronic obstructive pulmonary disease, acute
lung injury, and critical care illness may develop hypercapnia.
Many of these patients often have muscle dysfunction which
increases morbidity and impairs their quality of life. Here, we
investigated whether hypercapnia leads to skeletal muscle atro-
phy. Mice exposed to high CO2 had decreased skeletal muscle
wet weight, fiber diameter, and strength. Cultured myotubes
exposed to high CO2 had reduced fiber diameter, protein/DNA
ratios, and anabolic capacity. High CO2 induced the expression
of MuRF1 in vivo and in vitro, whereas MuRF1/ mice exposed
to high CO2 did not develop muscle atrophy. AMP-activated
kinase (AMPK), a metabolic sensor, was activated in myotubes
exposed to high CO2, and loss-of-function studies showed that
the AMPK2 isoform is necessary for muscle-specific ring fin-
ger protein 1 (MuRF1) up-regulation and myofiber size reduc-
tion. High CO2 induced AMPK2 activation, triggering the
phosphorylation and nuclear translocation of FoxO3a, and lead-
ing to an increase in MuRF1 expression and myotube atrophy.
Accordingly, we provide evidence that high CO2 activates skel-
etal muscle atrophy via AMPK2-FoxO3a-MuRF1, which is of
biological and potentially clinical significance in patients with
lung diseases and hypercapnia.
Hypercapnia, or elevation of blood CO2 levels, occurs in
patients with respiratory diseases such as chronic obstructive
pulmonary disease (COPD),4 where it is associated with worse
clinical outcomes (1– 4). Recent reports suggest that high CO2
levels can activate signaling pathways that, independently of
pH, have deleterious effects on the lung, impairing innate
immune response and the ability to fight infectious processes
(5–11). Patients with respiratory diseases develop muscle atro-
phy, which negatively affects their quality of life (12–14). Dur-
ing muscle atrophy, proteolytic systems are activated, and con-
tractile proteins and organelles are degraded causing shrinkage
of muscle fibers (15–17). The increased expression of the mus-
cle-specific ubiquitin-E3 ligases muscle RING finger 1 (MuRF1)
and the muscle atrophy F-box (atrogin-1/MAFbx) have been
described in several models of muscle atrophy (18, 19), and
their inactivation in mice attenuates muscle atrophy induced by
denervation and dexamethasone (20 –22).
AMP-activated protein kinase (AMPK) is a metabolic sensor
that is activated in response to cellular stress (23). The mam-
malian AMPK is a heterotrimeric enzyme complex with a cat-
alytic subunit () and regulatory subunits ( and ). The phos-
phorylation by upstream kinases of a conserved threonine
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residue (Thr-172) within the kinase domain of the -catalytic
subunit is required for AMPK activation (23). Recently AMPK
has been implicated in the control of muscle mass by increasing
protein degradation through the ubiquitin proteasome system
(UPS) and autophagy (24). AMPK activation was reported to
regulate myofibrillar protein degradation through the tran-
scription factor FoxO (25). Here we describe that hypercapnia,
by activating AMPK, leads to phosphorylation and nuclear
translocation of FoxO3a and MuRF1 up-regulation, which
results in skeletal muscle atrophy.
EXPERIMENTAL PROCEDURES
Reagents—All cell culture reagents were from Corning Life
Sciences (Tewksbury, MA). HRP-conjugated goat anti-mouse
secondary antibody was from Bio-Rad, and GAPDH and HRP-
conjugated goat anti-rabbit antibody were from Cell Signaling
Technology (Danvers, MA). All other chemicals were pur-
chased from EMD Millipore (Billerica, MA) or Sigma. Reagents
for production of cDNA and quantitative real time PCR (qPCR)
were from Bio-Rad and Life Technologies. The DNA and
mRNA isolation kits were from Qiagen (Germantown, MD).
Primers were purchased from Integrated DNA Technologies
(Coralville, IA). Restriction endonucleases were obtained from
Promega (Madison, WI).
Animals—Adult (14 –16 weeks old) male C57Bl/6 mice were
obtained from The Jackson Laboratory (Bar Harbor, ME), and
age-matched male MuRF1/ mice and wild-type littermates
(MuRF1/) on a 129S/C57Bl/6 background have been described
elsewhere (20, 26). For arterial blood gas measurements,
C57BL/6 mice with a common carotid artery catheter were pur-
chased from Charles Rivers Laboratories (Wilmington, MA).
All animals were provided with food and water ad libitum,
maintained on a 14-h light/10-h dark cycle, and handled
according to National Institutes of Health guidelines. All of the
procedures involving animals were approved by the Northwest-
ern University Institutional Animal Care and Use Committee.
For high CO2 exposure, animals were maintained in a hyper-
capnia chamber (BioSpherix Ltd., Lacona, NY) for 3, 7, 14, or 21
days. The chamber’s atmosphere was continuously monitored
and adjusted with ProOx/ProCO2 controllers (BioSpherix Ltd)
in order to maintain 10% CO2 and 21% O2, with a temperature
of 20 –26 °C and a relative humidity between 40 and 50%. These
settings resulted in an arterial partial pressure of carbon dioxide
(paCO2) of 75 mm Hg and arterial partial pressure of oxygen
(paO2) of 100 mm Hg, whereas in animals maintained in
room air paCO2 was 40 mm Hg and paO2 was 100 mm Hg
(7, 27). None of the animals developed appreciable distress. At
selected time points animals were anesthetized with Euthasol
(pentobarbital sodium/phenytoin sodium), soleus, gastrocne-
mius, and tibialis anterior muscles were excised, blotted dry,
and weighed. Muscles were then either frozen in liquid nitro-
gen-cooled isopentane for cryosectioning or snap-frozen in liq-
uid nitrogen for protein, RNA, or DNA extraction.
Arterial Blood Gases—Arterial blood gases were obtained
from unanesthetized, restrained mice with surgically implanted
carotid artery catheters. Mice were allowed to adapt for 1 to 2
days after shipping before being placed in the hypercapnia
chamber and before any arterial blood gases were drawn. Arte-
rial blood was analyzed for pH, PaCO2, PaO2, and HCO3 using
a pHOx Plus Blood Gas Analyzer (Nova Biomedical, Waltham,
MA) that was calibrated daily.
Immunohistochemistry and Fiber Size and Type Assess-
ment—Soleus, gastrocnemius, and tibialis anterior serial trans-
verse cryosections (8 m) were obtained from the Northwest-
ern University Mouse Histology and Phenotyping Laboratory
and mounted on glass slides. Sections were fixed in 4% formal-
dehyde, permeabilized, and blocked. Immunostaining was per-
formed with laminin primary antibody (1:50 dilution; Sigma)
followed by Alexa Fluor 568-conjugated secondary antibody
(1:200 dilution; Life Technologies). Type I fibers were stained
with anti-type I myosin heavy chain (A4.840, 1:50 dilution,
DSHB, Iowa City, IA), and type II fibers were stained with anti-
myosin (Skeletal, Fast)-alkaline phosphatase (Sigma). Images
were acquired with a Zeiss LSM 510 confocal microscope using
a 40 objective (Northwestern University Center for Advanced
Microscopy) and analyzed using Zeiss LSM5 Image Browser
software. Fiber size was studied by measuring the fibers’ mini-
mal inner diameter (at least 100 fibers per muscle), defined as
the minimum diameter from inner border to inner border,
passing through the center of the muscle fiber. This parameter
has been shown to be very insensitive to deviations from the
“optimal” cross-sectioning profile, as compared with direct
measure of fiber cross-sectional area (28). Cross-sectional area
(CSA) was calculated using this diameter, and results were
expressed as mean CSA  S.E. and as percentage of fibers dis-
tributed by size.
Grip Strength Test—Forelimb skeletal muscle strength was
assessed using a digital grip strength meter (Columbus Instru-
ments, Columbus, OH) as described (29). Grip strength was
measured in each animal six successive times, and the average
of the highest four values for each mouse was used.
Cell Culture, Adenoviral Infection, and Myotube Analysis—
C2C12 mouse myoblasts (ATCC, CRL1772) were cultured and
differentiated as described elsewhere (30). In brief, cells were
allowed to grow in p60 plates until they reached 90 –95% con-
fluence, and then culture media was changed to prewarmed 2%
horse serum DMEM (differentiation media). The differentia-
tion media was renewed every 18 –24 h, and cells were allowed
to differentiate for 4 – 6 days. The FoxO3 mutant bearing six
serine-to-alanine mutations on AMPK phosphorylation sites
was generously provided by Dr. Anne Brunet (Department of
Genetics, Stanford University, CA) (31). The sequence was
confirmed by traditional sequencing at the Northwestern
University Genomics Core Facility, and the construct was
incorporated into an adenoviral vector (Ad-FoxO3a-6A, Vec-
tor BioLabs, Malvern, PA). Commercially available wild-type
FoxO3-containing adenovirus vector (Ad-FoxO3a-WT, Vector
BioLabs) was used as a control. For infection, myotubes were
incubated with the corresponding adenovirus at six plaque-
forming units per cell for 24 h. Images were acquired using a
Nikon Eclipse TE2000-U inverted scope with a 40 objective.
Myotube diameters were quantified by measuring 160 tube
diameters (5–10 measurements per fiber) from five random
fields using MetaMorph Software (Molecular Devices, Sunny-
vale, CA).
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CO2 Medium and CO2 Exposure—For the different experi-
mental conditions, initial solutions were prepared with
DMEM/F-12/Tris base/MOPS (3:1:0.25:0.25) containing 2%
horse serum, 100 units/ml penicillin, and 100 g/ml streptomy-
cin. The buffering capacity of the medium was modified by
changing its initial pH with Tris base and MOPS to obtain a pH
of 7.4 at the various CO2 levels (pCO2 40, 60, and 120 mm Hg).
The desired CO2 and pH levels were achieved by equilibrating
the medium overnight in a humidified chamber (C-Chamber,
BioSpherix Ltd.). The atmosphere of the C-Chamber was con-
trolled with a ProCO2 carbon dioxide controller (BioSpherix
Ltd.). In this chamber cells were exposed to the desired pCO2
while maintaining 21% O2 balanced with N2. Before and after
CO2 exposure, pH, pCO2, and pO2 levels in the medium were
measured using a Stat Profile pHOx blood gas analyzer (Nova
Biomedical Corp.). Experiments were started by replacing the
culture medium with the CO2-equilibrated medium and incu-
bating in the C-Chamber for the desired time.
Transfection of C2C12 Cells with siRNA—After 3 days of dif-
ferentiation, media were removed from C2C12 cells and
replaced with antibiotic-free differentiation media, and trans-
fection was performed after 12 h. Before transfection, C2C12
myotubes were washed twice with DMEM and transfected with
mouse AMPK1 and -2, FoxO3a, and MuRF1 siRNA duplexes
(100 pmol) from Santa Cruz Biotechnology (Santa Cruz, CA) by
using Lipofectamine RNAiMAX (Life Technologies) according
to the manufacturer’s recommended protocol. Cells were incu-
bated with the RNA-Lipofectamine complexes for 4 – 6 h at
37 °C. After this period, the transfection complex was supple-
mented with differentiation media up to 3 ml, and experiments
were performed 48 h later. A scrambled siRNA was used as a
control (Life Technologies).
FIGURE 1. Hypercapnia causes muscle atrophy in mice without changes in metabolic phenotype. C57Bl/6 mice were exposed to 10% CO2 (HC) for 7, 14,
and 21 days or maintained in room air (CT), and soleus muscles were excised, frozen, and cryosectioned (8 m thickness). A, soleus muscle wet weight (n  7).
B, the upper panel shows soleus muscle cross-sections immunostained with laminin antibody. Scale bars, 50 m. n  4. The lower panel shows a histograms of
fiber size distribution. C, fiber CSA from soleus muscle of mice exposed to room air or 10% CO2 for 14 and 21 days. D, muscle force assessed via the grip strength
test (n  10). Results are represented normalizing the average grip of each mouse by the body weight at the corresponding day. E, percentage of type I and type
II fibers in soleus muscle of mice exposed to room air or 10% CO2 for 14, and 21 days (n  6). F, fiber CSA from type I and type II fibers from soleus muscle of mice
exposed to room air or 10% CO2 for 14 and 21 days ( n 6). *,p  0.05; **, p  0.01.
TABLE 1
Exposure to high CO2 causes normoxic hypercapnia
C57Bl/6 mice were exposed to control conditions at room air (CT, n  7) or high CO2/hypercapnia for different time points (HC-3 days, n  6; HC-5 days, n  3; HC-7 days,
n  3). Samples were analyzed with a pHOx Plus Blood Gas Analyzer, as described under “Experimental Procedures.”
Variable
Arterial blood gases
p ValueCT HC-3 days HC-5 days HC-7 days
paCO2 (mm Hg) 33  5.1 75  6.8 79  4.6 79  1.8 p  0.0001
paO2 (mm Hg) 89  6.1 109  7.8 103  11 111  1.1 p  0.05
pH 7.42  0.04 7.29  0.05 7.3  0.02 7.32  0.02 p  0.05
HCO3 (mmol/liter) 22  4.1 37  2.7 42  1.2 41  2.7 p  0.01
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Western Blot Analysis—C2C12 myotubes were homogenized
in Lysis Buffer (Cell Signaling Technology). Muscle samples
were homogenized on ice with cold lysis buffer in a 10-fold
(wt/wt) excess of lysis buffer, pH 7.6, that contained 8.7 mM
NaH2PO4, 58 mM Na2HPO4, 144 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate, 0.1% SDS, and 1 protease inhibi-
tor mixture (Roche Applied Science) as previously described
(32) using a Polytron PT 10-35 homogenizer (Thermo Scien-
tific, Waltham, MA). Samples were centrifuged at 22,000  g
for 10 min at 4 °C, and after 2 spins the final supernatant was
collected. Protein concentrations were determined by the BCA
assay (Thermo Scientific Pierce Protein Biology Products,
Rockford, IL). Proteins were separated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred to nitrocellulose membranes, immunoblotted, and visu-
alized by chemiluminescence following the manufacturer’s
instructions (Perkin Elmer Life Sciences). The following
commercially available antibodies and dilutions were used for
Western blotting: rabbit anti-pAMPK (Thr-172), anti-
AMPK, anti-pACC (Ser-79), anti-ACC, anti-GAPDH, and
anti-FoxO3a were from Cell Signaling Technology and used at
1:1000; rabbit anti-actin (1:2000) was from Sigma; rabbit anti-
MuRF1 (1:1000) was from ECM Biosciences (Versailles, KY);
rabbit anti AMPK1 (1:1000) was from EMD Millipore; rabbit
AMPK2 (1:1000) was from Novus Biologicals (Littleton, CO);
rabbit anti-Pol II (1:200) was from Santa Cruz Biotechnology.
Rabbit anti-pFoxO3 (Ser-588) was generously gifted by Dr.
Anne Brunet and used at a dilution of 1:500. Primary antibodies
were detected with horseradish peroxidase-conjugated second-
ary antibodies. Quantification of protein levels was performed
by densitometric scanning with ImageJ 1.29X (National Insti-
tutes of Health).
Immunoprecipitation—C2C12 cells were differentiated for 4
days and then transfected with Ad-Foxo3a-6A mutant or with
wild-type FoxO3a-containing adenovirus. Cell lysates were
prepared, and aliquots containing 1000 g of protein were
rotated overnight at 4 °C with FoxO3a antibody (1:200) or con-
trol IgG in the presence of 40 l protein A/G-agarose beads
(Santa Cruz Biotechnology). Samples were then centrifuged,
and the beads were resuspended in SDS-loading buffer and sep-
arated in a 10% polyacrylamide gel.
RNA Extraction, cDNA Synthesis, and Quantitative RT-PCR—
Quantification of ribosomal DNA transcription was done as
previously described (33). Muscle RNA was extracted using
FIGURE 2. Hypercapnia causes muscle atrophy in gastrocnemius and tibialis anterior. C57Bl/6 mice were exposed to 10% CO2 (HC) for 14 and 21 days or
maintained in room air (CT), and gastrocnemius and tibialis anterior muscles were excised, frozen, and cryosectioned (8-m thickness). Muscle cross-sections
immunostained with laminin antibody are shown. Scale bars, 50 m. A, tibialis anterior. B, gastrocnemius. n  4. *, p  0.05.
FIGURE 3. High CO2 exposure causes a time-dependent increase in nuclear centralization in myofibers. Histological analysis of myofibers from soleus
muscle sections with H&E staining from mice exposed to room air or 10% CO2 levels for 7, 14, and 21 days. The graph represents the number of centralized
nuclei normalized by the number of fibers. Scale bars, 100 m. n  3. Arrows indicate centralized nuclei. Representative images were taken at 60. *, p  0.05.
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TRIzol reagent (Life Technologies). Total RNA was determined
spectrophotometrically using a Nanodrop ND-1000 (Saveen &
Werner, Limhamnsvägen, Sweden) at 260 nm and quality-as-
sessed visually using agarose gel electrophoresis. cDNA was
synthesized using Superscript VILO cDNA synthesis kit (Life
Technologies). Quantitative RT-PCR was performed using
GoTaq qPCR Master Mix (Promega) on a CFX384 Real-time
PCR detection system (Bio-Rad). The primers used were
5	-CCA AGT GTT CAT GCC ACG TG-3	 (forward) and
5	-CGA GCG ACT GCC ACA AAA A-3	 (reverse). Each sam-
ple was run in triplicate, and relative expression levels of tran-
scripts of interest were calculated using the comparative Ct
(

Ct) method with glyceraldehyde-3-phosphate dehydroge-
nase as housekeeping gene. Data were analyzed using the Bio-
Rad CFX manager software (Version 2.0).
Centralized Nuclei Analysis—8-m frozen soleus muscle
sections were stained with hematoxylin and eosin (H&E), and
histological images were acquired at 40 magnification using
the Zeiss Axioskop upright brightfield microscope with a CRi
NUANCE spectral camera. Low magnification (10) images
that captured the entire soleus muscle in cross-section were
used to count the centralized/internal nuclei. The total number
of fibers counted in each cross-section was between 600 and
700. The total number of myofibers counted was similar
between all the mice analyzed.
Evaluation of FoxO3 Nuclear Translocation—C2C12 myo-
tubes were harvested and then nuclear/cytosol fractionation
was performed with a commercially available kit (BioVision,
Milpitas, CA) according to the manufacturer’s instructions.
The nuclear fraction was then sampled, and proteins were sep-
arated by SDS-PAGE, transferred to nitrocellulose membranes,
and immunoblotted with anti-FoxO3a antibody. To assess the
phosphorylation of FoxO3a in the nuclear fraction, we trans-
fected C2C12 with Ad-FoxO3a-WT, and after 24 h cells were
exposed to high CO2 for 4 h, and the nuclear fractions were
isolated. FoxO3a was immunoprecipitated from the nuclear
fraction, and phosphorylation was assessed by Western blot
with the phospho-Ser-588 antibody.
Protein/DNA Ratio Determination—C2C12 myotubes were
exposed to high CO2 levels for 24 h, and then samples were
homogenized by sonication (Branson Sonifer 250). The total
amount of protein was measured with a Bradford assay, and
total DNA was measured with the fluorochrome Hoechst
33258, both from Bio-Rad, in a Fluoroskan Ascent FL Micro-
plate Fluorometer (Thermo Scientific).
Statistics—Data are expressed as the mean  S.E. When
comparisons were performed between two groups, significance
was evaluated by Student’s t test, and when more than two
groups were compared, analysis of variance was used followed
by the Dunnett test using GraphPad Prism software. Results
were considered significant when p  0.05.
RESULTS
Hypercapnia Causes Skeletal Muscle Atrophy in Mice—To
investigate whether high CO2 causes muscle atrophy, mice
were exposed to 10% CO2 and 21% O2 (hypercapnia) or to room
air (normocapnia), and skeletal muscle wet weight, fibers CSA,
and grip strength were assessed, and arterial blood gases were
FIGURE 4. High CO2 exposure causes reduction in myotube diameter associated with a decrease in total protein content and down-regulation of
anabolic genes. A, representative images of C2C12 myotubes exposed to 40, 60, and 120 mm Hg CO2, and the graph depicts average myotubes diameter (n 
3). Scale bars, 30 m. B, representative images of C2C12 myotubes exposed to 0 (CT), 6, 24, and 48 h CO2 (n  3). C, protein/DNA ratio of C2C12 myotubes
exposed to 40 mmHg (CT) or 120 mmHg (HC) for 24 h, as measured with the fluorochrome Hoechst 33258 (n  3). D, activation of the anabolic 45 S pre-rRNA
gene as measured with real time PCR using specific primers (n  5). **, p  0.01; ***, p  0.001.
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measured (Table 1). Also, mice breathing high CO2 had
decreased soleus muscle wet weight as compared with room
air-breathing mice (Fig. 1A). Fig. 1B, upper panel, shows images
of laminin-stained soleus cryosections in which quantitative
analysis indicated a decrease in CSA during hypercapnia (Fig.
1C). In agreement with these findings, Fig. 1B, lower panel,
shows a leftward shift in the size distribution histogram indi-
cating a predominance of thinner fibers in muscles from hyper-
capnic mice. Muscle strength was also decreased in mice
exposed to high CO2, as assessed by the grip strength method
(Fig. 1D). Soleus muscles are composed by muscle fiber type I
and II. We did not observe a change in the soleus’ fiber compo-
sition or a predominant fiber’s type atrophy with both type of
fibers decreasing their CSA by 20 –25%, which is consistent
with the data in Fig. 1C (Fig. 1, E and F). The atrophic effect
induced by hypercapnia on the soleus muscle was also observed
in the gastrocnemius and tibialis anterior (Fig. 2, A and B) from
mice exposed to CO2 for 14 and 21 days, suggesting that the
decrease in fiber size caused by hypercapnia is a generalized
effect. Also, soleus muscle from hypercapnic mice displayed a
time-dependent increase in myonuclear centralization respec-
tive to the total number of fibers (Fig. 3), likely representing
tissue response to injury (34). Moreover, the data show that at
21 days there was a significant increase in the percentage of
fibers with centralized nuclei (1.007.227 versus 3.007.009
p  0.01 n  3).
High CO2 Leads to Decreased Myotube Diameter, Protein
Abundance, and Down-regulation of Anabolic Genes—C2C12
myotubes exposed to increasing levels of CO2 became progres-
sively thinner (Fig. 4A), with significant differences observed
after 24 h of exposure (Fig. 4B). Therefore, all the subsequent in
vitro experiments were performed at 24 h and 120 mm Hg (des-
ignated as “hypercapnia”) as we observed the highest effect at
this level. To further explore the effect of hypercapnia on myo-
tube diameter, we measured total protein content (protein/
DNA ratio) and observed that myotubes exposed to hypercap-
nia had lower protein content at 24 h (Fig. 4C). We also found a
time-dependent decrease in the expression of the 45 S pre-
rRNA transcripts, a marker of de novo RNA synthesis (Fig. 4D).
MuRF1 Mediates the High CO2-induced Myotube Atrophy—
To determine whether the ubiquitin proteasome system was
involved in high CO2-induced skeletal muscle atrophy, we
treated myotubes with the proteasome inhibitor MG-132 (10
M for 12 h) or the ubiquitin-conjugating enzyme inhibitor
(UBE1; 10 M for 12 h) and exposed them to hypercapnia.
Dexamethasone (10 M) was used as a positive control of UPS-
mediated muscle atrophy (21). As shown in Fig. 5, MG-132 and
UBE1 prevented the hypercapnia-induced reduction in myo-
tube diameter, and the effect of dexamethasone (a positive con-
trol) was prevented with MG-132. We assessed MuRF1 expres-
sion in myotubes and soleus muscle from mice exposed to
hypercapnia and found significant increases in MuRF1 expres-
sion in myotubes (Fig. 6A) and in soleus muscle (Fig. 6B). To
determine whether MuRF1 is required for hypercapnia-in-
duced myotube atrophy, we transfected differentiated myo-
tubes with MuRF1 small interfering RNA (siRNA) and found
that silencing MuRF1 had a protective effect against hypercap-
nia-induced myotube atrophy (Fig. 6C). To validate these find-
ings and assess the role of MuRF1 in vivo, we exposed
MuRF1/ mice to high CO2 for 21 days and found that the
absence of MuRF1 prevented the reduction in muscle strength
(Fig. 7A), a decrease in soleus mean fiber CSA (Fig. 7B), and the
leftward shift in fiber size distribution observed in MuRF1/
mice (Fig. 7C).
Hypercapnia Causes Muscle Atrophy via AMPK-dependent
Pathway—Exposure of myotubes to hypercapnia led to an
increase in both AMPK and its target acetyl-CoA carboxylase
(ACC) phosphorylation, which occurred as early as 15 min and
lasted for at least 24 h (Fig. 8A). AMPK has recently been shown
to mediate skeletal muscle protein degradation via atrogin-1
and MuRF1 (25, 35). To determine whether AMPK is a neces-
sary mediator of high CO2-induced muscle atrophy, myotubes
were transfected with scrambled or specific AMPK1 or -2
siRNA. We found that AMPK2, but not AMPK1, was neces-
sary for CO2-induced decrease in myotube diameter (Fig. 8B).
Furthermore, we also found that high CO2-driven up-regula-
tion of MuRF1 is mediated by AMPK2, as MuRF1 induction
was abrogated in high CO2-exposed cells transfected with
AMPK2 siRNA (Fig. 8C).
FIGURE 5. Ubiquitin-proteasome system mediates CO2-induced myotube
atrophy. Representative graph and images of C2C12 myotubes treated with
vehicle, MG-132, and E1-inhibitor UBE1 exposed to 40 mmHg (CT) or 120
mmHg (HC) CO2 for 24 h or pretreatment with MG-132 or vehicle (V) and
exposed to dexamethasone for 12 h (Dexa, 10 M) (n  3). Scale bars, 30 m.
***, p  0.001.
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FIGURE 6. MuRF1 regulates high CO2-induced reduction in myotube diameter. A and B, representative immunoblots of C2C12 myotubes (A) and soleus
muscle lysates (B) exposed to CO2 for increasing times and probed with an antibody specific for MuRF1 (n  3). C, representative graph and images of C2C12
myotubes transfected with scrambled (Scr) or specific MuRF1 siRNA and exposed to 40 mmHg (CT) or 120 mmHg (HC) CO2 for 24 h (n  3). Scale bars, 30 m.
The graph represents the average myotubes diameter. Representative immunoblots of MuRF1 (transfection control), actin, and GAPDH (loading controls).
*, p  0.05; **, p  0.01; ***, p  0.001.
FIGURE 7. MuRF1/ mice are protected against high CO2-induced muscle atrophy. MuRF1
/ mice and wild-type littermates (MuRF1/) were exposed
to 10% CO2 (HC) for 21 days or maintained in room air (CT), and soleus muscles were excised, frozen, and cryosectioned (8-m thickness). A, measured grip
strength from MuRF1/ mice and wild-type littermates. n  6. Results are represented normalizing the average grip of each mouse by the body weight (BW)
at the corresponding day. B, soleus muscles from MuRF1/ mice and wild-type littermates were immunostained with laminin antibody and fiber CSA was
analyzed. n  3). Scale bars, 50 m. C, fiber size distribution histograms from MuRF1/ mice and wild-type littermates (n  6). *, p  0.05.
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Hypercapnia Causes AMPK2-dependent FoxO3a Nuclear
Translocation, Which Is Needed for MuRF1 Up-regulation and
Reduction in Myotube Diameter—As shown in Fig. 9A, hyper-
capnia led to FoxO3a nuclear translocation, which was pre-
vented by silencing AMPK2 but not AMPK1 (Fig. 9B). More-
over, transfection of myotubes with scrambled or specific
FoxO3a siRNA revealed that silencing FoxO3a prevented the
high CO2-induced up-regulation of MuRF1 and the decrease in
myotube diameter (Fig. 9, C and D).
AMPK Phosphorylates FoxO3a, Which Regulates MuRF1 during
Hypercapnia-induced Reduction in Myotube Diameter—It has
been reported that AMPK regulates FoxO3a phosphorylation
(31, 36) and that it directly phosphorylates FoxO3a and that
mutation of Thr-179, Ser-399, Ser-413, Ser-555, Ser-588, and
Ser-626 to alanine (FoxO3a-6A) results in a reduction of
AMPK-dependent phosphorylation of FoxO3a (31). To assess
whether hypercapnia leads to AMPK-dependent phosphoryla-
tion of FoxO3a, myotubes were transfected with an adenovirus
coding for FoxO3a wild type (Ad-FoxO3a-WT) or mutated at
the six AMPK phosphorylation sites. After FoxO3a immuno-
precipitation, Western blots probed with an antibody that spe-
cifically recognizes Ser(P)-588 but does not recognize the non-
phosphorylated form (31) showed that high CO2 levels
increased Ser-588 phosphorylation only in FoxO3a-WT (Fig.
10A). Moreover, the phosphorylated form of FoxO3a is present
in the nuclei (Fig. 10B). Overexpression of Ad-FoxO3a-6A pre-
vented the high CO2-induced up-regulation of MuRF1 (Fig.
10C) and the decrease in myotube diameter (Fig. 10D), indicat-
ing that hypercapnia leads to AMPK-dependent phosphoryla-
tion of FoxO3a, which is necessary to up-regulate MuRF1
expression and decrease myotube diameter.
DISCUSSION
Muscle atrophy is being increasingly recognized as a major
contributor to worse clinical outcomes in patients with pulmo-
nary diseases (4, 37, 38), and indeed recovery of lower limbs
muscle mass of COPD patients in the setting of pulmonary
rehabilitation has proven to be beneficial (39). Muscle atrophy
is characterized by a decrease in muscle fiber diameter, protein
content, and force production (24). We report here that hyper-
capnia, which occurs in patients with chronic respiratory dis-
eases, causes skeletal muscle atrophy. It has been reported that
tobacco smoke, which is rich in CO2 and causes COPD, is also
associated to muscle dysfunction even in early stages of lung
FIGURE 8. AMPK regulates myotube atrophy and MuRF1 up-regulation during exposure to high CO2. A, AMPK and acetyl-CoA carboxylase (ACC) phos-
phorylation in myotubes exposed to 40 mmHg (CT) or 120 mmHg (HC) hypercapnia for different time points, as shown by immunoblots of samples probed with
specific antibodies (n  3). B, representative graph and images of myotubes diameters transfected with scrambled (Scr), AMPK1 or 2 siRNA and exposed to
high CO2. Scale bars, 30 m. C, myotubes were transfected with Scr, AMPK1 or -2 siRNA and exposed to high CO2. Representative immunoblots of cell lysates
are shown with specific antibodies. Samples were probed with MuRF1 specific antibody to detect its level of induction under the different conditions (n  3).
Actin was used as a loading control. *, p  0.05; ***, p  0.001.
Hypercapnia Leads to Skeletal Muscle Atrophy
9190 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 14 • APRIL 3, 2015
FIGURE 9. Hypercapnia causes AMPK2-dependent FoxO3a nuclear translocation, which is necessary for MuRF1 up-regulation and reduction in
myotube diameter. A, representative immunoblots from myotubes exposed to 40 mmHg (CT) and 120 mmHg (HC) CO2; nuclear fractions were obtained, and
samples were incubated with FoxO3a specific antibody (n  5). B, representative immunoblots from myotubes exposed to high CO2; myotubes were trans-
fected with scrambled (Scr), AMPK1 or -2 siRNA, nuclear and cytosolic fractions were obtained, and samples were incubated with FoxO3a-specific antibody
(n  3). C, representative immunoblots from myotubes exposed to high CO2 for 24 h; myotubes were transfected with Scr or FoxO3a siRNA and probed with
MuRF1 specific antibodies (n  3). D, representative graph and images of C2C12 cells transfected with Scr or FoxO3a siRNA and exposed to high CO2 for 24 h
(n  3). Polymerase II and actin were used as loading controls. Scale bars, 30 m. *, p  0.05.
FIGURE 10. Both high CO2-induced up-regulation of MuRF1 and myotube atrophy require FoxO3a phosphorylation by AMPK. A, representative blots
from immunoprecipitation of FoxO3a obtained from myotubes previously infected with Ad-WT-FoxO3a and Ad-FoxO3a-6A and then exposed to 40 mmHg
(CT) and 120 mmHg (HC) CO2. Blots were analyzed using Ser(P)-588 antibody (n  3). B, representative blots from immunoprecipitation of FoxO3a from nuclear
fractions of myotubes previously infected with Ad-WT-FoxO3a and exposed to high CO2 for 4 h. Blots were analyzed with 588 antibody and FoxO3a and
polymerase II (pol II) as a loading control. n  3. C, representative immunoblots from myotubes exposed to high CO2 for 24 h; myotubes were previously
transfected with Ad-WT-FoxO3a-6A and Ad-FoxO3a-6A and probed with MuRF1 specific antibodies. Total FoxO3a was used as a loading control (n  4). D,
representative graph and images transfected with Ad-WT-FoxO3a-6A and Ad-FoxO3a-6A and exposed to high CO2 for 24 h (n  3). Scale bars, 30 m. *, p 
0.05; **, p  0.01; ***, p  0.001.
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disease (40). We observed that animals exposed to high CO2
had high PaCO2 and also, with time, higher bicarbonate values
(Table 1), reflecting renal compensation of the respiratory aci-
dosis. We found that exposing mice to high CO2 levels similar
to those observed in hypercapnic patients with COPD (41)
leads to muscle atrophy as evidenced by a progressive decrease
in muscle mass, fibers cross-sectional area, and limb grip
strength. Hypercapnia did not cause selective fiber type atrophy
in the soleus muscle or a switch from slow-twitch to fast-twitch
fibers, however, the antibody used in the study does not distin-
guish among the different type II fibers; thus, a switch from type
IIa to IIb cannot be excluded (see Fig. 1, E and F). We show that
high CO2 results in more centralized nuclei in the soleus muscle
(Fig. 3), which represents a tissue response to myofiber injury
(34). Although skeletal muscle atrophy has not classically been
associated to cellular damage and repair but to an imbalance of
protein turnover, a recent study shows that cancer-associated
muscle atrophy is characterized by cellular injury and repair
with activation and proliferation of satellite cells (42). There-
fore, our finding of nuclear centralization could similarly sug-
gests myofiber response to high CO2-mediated injury.
Cultured myotubes exposed to high CO2 levels undergo a
dose- and time-dependent atrophy that was prevented by
MG-132 and UBE1, suggesting a role for the UPS in this pro-
cess. The UPS has been described to regulate skeletal muscle
atrophy in patients with chronic lung diseases (43– 46). In addi-
tion, there have been reports of skeletal muscle atrophy via the
UPS during acute lung injury and in patients with pulmonary
vascular disease (47– 49). Our data suggest a direct link
between hypercapnia and muscle atrophy via the UPS in this
process. Moreover, we found that hypercapnia in vivo and in
vitro increases the expression of MuRF1 (Fig. 6, A and 6),
whereas we did not find an increase in atrogin-1 (data not
shown).
AMPK has been reported to play a role in skeletal muscle
atrophy (23). We observed that the hypercapnia-dependent
activation of AMPK in cultured myotubes occurs very early
during high CO2 exposure and persists for at least 24 h. Previ-
ous evidence suggest that AMPK mediates muscle catabolism
through increased expression of FoxO transcription factors
(50), and AICAR-induced AMPK activation of atrogin-1 and
MuRF1 (25). Also, up-regulation of AMPK along with an
increase ubiquitin-protein conjugates and MuRF1 gene tran-
scription has been reported in skeletal muscles of patients with
COPD (51). We found that hypercapnia-driven muscle atrophy
is mediated by AMPK2, which is the major catalytic subunit
isoform in muscle (23). Previous evidence from lung alveolar
epithelialcellssuggeststhatCO2-mediatedAMPK1phosphor-
ylation occurs through Ca2/calmodulin-dependent kinase
kinase  (CaMKK-) (27), making this pathway a possible acti-
vator of AMPK in the present model. Alternatively, given that
CO2 exposure was found to cause mitochondrial dysfunction,
decreased O2 consumption, and ATP production in fibroblasts
and alveolar epithelial cells (52), AMPK activation could also
occur via LKB1. Interestingly, it has been reported that
AMPK2 activity is more dependent on high AMP levels than
the 1 isoform (53), making CO2-driven mitochondrial dys-
function an interesting potential upstream activator of AMPK,
which should be further addressed in future works. Other
mechanisms such as inhibition of protein phosphatases or acti-
vation of a different upstream kinase could also be relevant in
the present model (54).
We also found that hypercapnia decreased the expression of
45 S pre-rRNA, which is the precursor of the ribosomal RNA
components 28 S, 18 S, and 5.8 S. Increased transcription of the
45 S pre-rRNA is one of the earliest events in muscle hypertro-
phy (33, 55), and its expression is rapidly down-regulated in
atrophying skeletal muscle, indicating a reduction in the ana-
bolic capacity of the muscle during catabolic stress (56). AMPK
is known to down-regulate rRNA synthesis by phosphorylating
the RNA polymerase I-associated transcription factor TIF-IA
(57), preventing the assembly of functional transcription initi-
ation complexes. Thus, it appears that in addition to regulating
the expression of MuRF1 and muscle catabolism, hypercapnia
exposure also leads to the attenuation of the anabolic capacity
of muscle cells.
A recent study showed that acute lung injury associated mus-
cle atrophy requires the activation of the NF-B for MuRF1 to
be induced, whereas our findings suggest that high CO2 triggers
muscle catabolism through FoxO3a and MuRF1 regulation
(49). FoxO regulation in response to external stimuli is mostly
determined by changes in its phosphorylation state and subcel-
lular localization, which modulates its access to nuclear DNA
(58). Different kinases, including Akt, mitogen-activated pro-
tein kinases, and AMPK, have been shown to regulate FoxO
activation (59), and Greer et al. (31) have described that AMPK
directly phosphorylates FoxO3a and that AMPK is necessary
and sufficient for the phosphorylation of FoxO3a. We found
that high CO2 levels cause AMPK-dependent phosphorylation
of FoxO3a and that when FoxO3a-6A mutant is overexpressed,
the phosphorylation of the AMPK-targeted site Ser-588 is pre-
vented. Hypercapnia leads to AMPK2-dependent nuclear
translocation of FoxO3a, which regulates MuRF1 expression
leading to muscle atrophy. Although AMPK has been shown to
modulate FoxO3a expression through a PGC-1-dependent
FIGURE 11. A schematic model depicting that hypercapnia triggers skel-
etal muscle atrophy though a pathway that involves the activation of
AMPK2, phosphorylation of FoxO3a, and induction of MuRF1-
expression with subsequent skeletal muscle degradation.
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mechanism (60), we did not find changes in total cellular
FoxO3a abundance during high CO2 exposure (see Fig. 9, C and
D). AMPK phosphorylates FOXO3a at amino acids that are
different from the sites described for other kinases (Akt, SGK
(serum- and glucocorticoid-inducible kinase), CK1, DYRK1,
JNK, IKK-, and MST1) (31). Interestingly, like AMPK, Akt also
controls protein synthesis and protein degradation (16).
FoxO3a is one of the intersection points between both path-
ways as activation of Akt phosphorylates FoxOs, which
excludes them from the nuclei, preventing their functions as
transcription factors (16, 58).
In summary, we report that hypercapnia triggers skeletal
muscle atrophy though a pathway that involves the activation of
AMPK2, phosphorylation of FoxO3a, and induction of
MuRF1 (Fig. 11). This pathway is of pathophysiological rele-
vance to patients with hypercapnic respiratory diseases.
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